Bayer (BAYN) Given a €69.00 Price Target at Independent Research

Bayer (FRA:BAYN) received a €69.00 ($80.23) target price from Independent Research in a research report issued on Thursday. The brokerage presently has a “neutral” rating on the healthcare company’s stock. Independent Research’s price objective indicates a potential upside of 8.58% from the company’s previous close.

A number of other research firms also recently commented on BAYN. JPMorgan Chase & Co. set a €120.00 ($139.53) price objective on Bayer and gave the stock a “buy” rating in a research note on Monday, August 13th. Commerzbank set a €111.00 ($129.07) price objective on Bayer and gave the stock a “buy” rating in a research note on Monday, August 13th. Barclays set a €110.00 ($127.91) price objective on Bayer and gave the stock a “buy” rating in a research note on Monday, August 13th. Goldman Sachs Group set a €116.00 ($134.88) price objective on Bayer and gave the stock a “buy” rating in a research note on Monday, August 13th. Finally, Cfra set a €100.00 ($116.28) price objective on Bayer and gave the stock a “buy” rating in a research note on Tuesday, August 14th. Six equities research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average target price of €91.25 ($106.10).

Shares of Bayer stock opened at €63.55 ($73.90) on Thursday. Bayer has a 1-year low of €91.58 ($106.49) and a 1-year high of €123.82 ($143.98).

About Bayer

Bayer Aktiengesellschaft operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, Crop Science, and Animal Health segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents.

Featured Story: What are the reasons investors use put options?

Analyst Recommendations for Bayer (FRA:BAYN)

Receive News & Ratings for Bayer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply